India's weight-loss drug shows promise, says WHO
The World Health Organisation (WHO) has backed the use of semaglutide-based weight-loss drugs, including those manufactured in India, stating they can play a significant role in tackling the global obesity and non-communicable disease (NCD) crisis. The WHO highlighted that under medical supervision, these drugs help reduce body weight, improve metabolic health, and lower the risk of heart disease and type 2 diabetes. The organization urged countries, including India, to ensure wider access to such treatments, particularly for people with obesity and related conditions, while making them more affordable.
Key Points
- WHO has endorsed semaglutide-based weight-loss drugs for obesity, diabetes, and heart health under medical supervision.
- India's role as a manufacturer is highlighted for expanding local production and improving treatment availability.
- Semaglutide functions as a GLP-1 receptor agonist, originally developed for type 2 diabetes to regulate appetite and reduce food intake.
- The organization stresses the need for wider access and affordability to tackle growing public health challenges related to NCDs.
Exam Facts
- Semaglutide is a GLP-1 receptor agonist originally developed for type 2 diabetes management.
- The drug aids in regulating appetite, reducing food intake, and slowing gastric emptying under medical supervision.
- Obesity and NCDs remain a growing public health challenge globally and in India.
Read it. Retain it. Recall it.
Get spaced-repetition flashcards, daily quizzes and offline access — free on Android.